Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PI3K pathway biomarker side study in everolimus + exemestane-treated advanced breast cancer
NL-OMON46855Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of everolimus and exemestane in breast cancer, sponsored by Vrije University Medical Center. Primary endpoints: Progression biomarker study and Progression-free survival by PI3K pathway activation. Started Mar 2014; status: active, not recruiting.
02
Drugs
everolimusexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON46855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46855.